173 results about "Amniotic Sheet" patented technology

The present invention provides a dried amnion which is dried with maintaining tissues of a raw amnion and can be easily stored for a prolonged period of time. An amnion which is dried with maintaining cells and tissues of a raw amnion can be produced by repeating a pressure-reducing operation and a pressure-recovery operation several times, the pressure-reducing operation comprising continuously heating a raw amnion placed in a treatment vessel by a far-infrared heater provided in the treatment vessel and reducing the pressure of the inside of the treatment vessel, and the pressure-recovery operation comprising recovering the reduced pressure of the inside of the treatment vessel with heating the amnion by microwaves irradiated from a microwave heating apparatus provided outside of the treatment vessel, and the amnion is characterized by retaining basement membranes and connective tissues which are constituents of the raw amnion.

The invention relates to a preparing method and application of an amniotic membrane, in particular to a preparing method and application of an acellular amniotic membrane used for repairing skin wound difficult to heal. The preparing method specifically comprises the steps of isolating, cleaning and sterilizing an amniotic membrane tissue; arranging and drying the amniotic membrane tissue on a nitrocellulose membrane to manufacture an amniotic membrane paster; vibrating and digesting the amniotic membrane paster in mixed digestive fluid of 0.25%-0.5% of pancreatin and 0.2-0.5g/L EDTA.4Na for 10-30 minutes at a temperature of 37 DEG C; rinsing the amniotic membrane paster in TE buffer solution; vibrating overnight to fully remove amniotic membrane cells in TE-TritonX-100 solution; washing the amniotic membrane paster for three times in TE solution; vibrating and degrading the amniotic membrane paster for 2-4 hours in nucleic acid degrading solution at a temperature of 37 DEG C; washing the amniotic membrane paster for three times in the TE solution. The prepared acellular amniotic membrane paster can be stored for a long time after being refrigerated, dried, packed and sterilized by cobalt 60 irradiation and is a tissue engineering material which can be taken and used when needed. The acellular amniotic membrane paster can be easily separated from the nitrocellulose membrane to be used for repairing the skin wound after rewatered.

The invention relates to an amnion substrate covered blood vessel internal support and relative production. Wherein, it covers and decorates the blood vessel internal support and plants the endothelium cell, to avoid narrow condition; the support is formed by blood vessel internal support, amnion substrate covering the support, and the endothelium cell planted on the substrate. And the production comprises that removing cells of amnion, to be biological film with substrate film and dense layer; covering and decorating it on the blood vessel internal support, to form smooth and flat film on the inner surface; then planting the endothelium cell, to form a liner, as one inner layer of blood vessel sample, and approach the surface of support to the inner wall of vessel, to increase the bioavailability and blood compatibility.

Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

The invention relates to a method for extracting sub-totipotent stem cells from a chorion of a fetal surface of a placenta. The method comprises the steps of removing an amnion and stagnated blood from the placenta, and then repetitively washing the surface of the placenta to perform sterilization; shearing the chorion of the fetal surface in a glass utensil, removing placenta lobule tissues remained on the surface as much as possible, and shearing the chorion into small blocks; washing small tissue blocks by using a screen and a great amount of normal saline, and removing residual blood cells; performing tissue digestion: performing oscillatory digestion in a constant temperature shaker by using mixed enzymes; adding a proper amount of FBS for termination after digestion, performing filtration through a filter screen, and adding a great amount of normal saline to wash filter residues to obtain cells as many as possible; performing centrifugation, abandoning supernatant, adding saline water for washing and performing centrifugation to obtain mononuclear cells; performing magnetic bead sorting (OCT-4 positive, Nanog positive and STRO-1 negative) to obtain target cells. The invention further relates to the sub-totipotent stem cells obtained by adopting the method and pharmaceutical use thereof. The sub-totipotent stem cells have excellent characteristics.

The invention discloses four cell types which have wide heteroplastic transplantation application prospect and can be effectively induced into induced pluripotent stem (iPS) cells. The origins of three cell types are placental tissue, namely amnion mesenchymal cell, chorion mesenchymal cell and umbilical cord mesenchymal cell; and the origin of the other one is amniotic fluid cell. Besides, the invention also discloses an induction reprogramming method for producing cells capable of producing induced pluripotent stem (iPS) cells by efficient induction, including the following steps: cDNA containing pluripotent stem cell factor is respectively introduced into the four primary culture cells; the four primary cells in which cDNA is introduced are respectively cultured on appropriate culture mediums, primary iPS is obtained and then quality of iPS is optimized on appropriate culture mediums, and cloning of pluripotent stem cell can be primarily evaluated. In the invention, three mesenchymal cells of placenta origin and amniotic fluid cell all can be induced into iPS, wherein the chorion mesenchymal cell is compared with fibroblast, efficiency of induction reprogramming is improved by over 100 times, efficiency is about 2.3%, and the efficiency is slightly higher than that of horny cell; and a means which is more effective and more pertinent is provided for building disease model, screening drug and controlling oriented differentiation.

The invention discloses a preparation method of an autologous mesenchymal stem cell-loaded human amniotic membrane cornea paster, wherein autologous sourced mesenchymal stem cells are planted onto an amniotic membrane to be taken as bearing carriers to treat the corneal injury. The method comprises the following steps of: inoculating monocyte separated from bone marrow into an alpha-MEM culture medium, amplifying to a third generation to inoculate 2.5*10<5> cells onto the 1.2cm*1.2cm amniotic membrane, and tightly arranging the cells after 48 hours, wherein the cover area of the mesenchymal stem cell under an inverted microscope is greater than 80%, and the immunofluorescent staining shows that the positive rate of cells CD44 and CD90 is greater than 90%. The human amniotic membrane-loaded mesenchymal stem cell paster is free from dissolving and falling after being transplanted within one week, and new vessels can not be generated within eight months. The method is free from immunological rejection, an enough cell source can be provided, and the method can be used for the clinic treatment of the corneal injury.

The invention discloses an alpha-thalassemia screening kit and application thereof in prenatal screening and belongs to the technical field of prenatal screening of alpha-thalassemia. The alpha-thalassemia screening kit comprises a negative control sample, a positive control sample, PCRmasterMIX, and a PCR primer. Application of the alpha-thalassemia screening kit includes: amplifying fetal DNA in maternal peripheral blood by the designed primer so as to perform prenatal screening on alpha-thalassemia. The maternal peripheral blood is collected for prenatal screening of alpha-thalassemia, with no need for puncturing the amnion cavity and inserting pile tissue and with no injury to fetus, and the alpha-thalassemia screening kit is safe and reliable; accuracy is up to 99.99%; the technical blank of noninvasive prenatal screening of alpha-thalassemia is filled, and fewer children with diseases are born.

The invention discloses a method and a kit for acquiring amniotic mesenchymal stem cells. The method comprises the following steps: carrying out first digestion treatment on an amniotic membrane by adopting a first enzymic preparation, and abandoning digestion liquid, thus obtaining a first digestion product; carrying out second digestion treatment on the first digestion product by adopting a second enzymic preparation, and abandoning digestion liquid, thus obtaining a second digestion product; and separating the amniotic mesenchymal stem cells from the digestion product, wherein the first enzymic preparation comprises a trypsin-EDTA mixed solution, the second enzymic preparation comprises collagenase and DNase I. With the adoption of the method and the kit for acquiring the amniotic mesenchymal stem cells provided by the invention, a number of amniotic mesenchymal stem cells with high purity and high activity can be obtained.

The present invention relates to a human amniotic epithelial cell separation method, which comprises: 1, collecting and transporting placenta; 2, tearing and taking the amnion; 3, rinsing the amnion; 4, cutting the amnion; 5, digesting the amnion epithelium surface; 6, terminating the digestion; 7, collecting cells through centrifugation; and 8, resuspending the amniotic epithelial cells, and carrying out inoculating culture. According to the present invention, the high purity amniotic epithelial cells can be separated, the number of the cells is more, the cell activity is high, and the basis is established for the research and the clinical applications of the amniotic epithelial cells.

Intrauterine fetal growth restriction (IUGR) is an affliction of a disparaging spectrum, placental insufficiency being the major inciting pathology. The resultant fetal hypoglycemia is alleviated by intravenous hypertonic D-glucose 25-50% maternal supplements, by improving the Vmax of placental transfer for D-glucose, in accordance with Michaelis-Menten model of substrate transfer. Fetal normoglycemia so restored in turn surprisingly improves fetal hypoxia, hypercapnia, hyperlacticemia, acidosis, hypertriglyceridemia, oliguria/hydromnios, and the fetal nutrient/mineral/vitamin acquisition. The list being phenomenal can only convince an inquiring reader by a biochemical sojourn into the aquatic world of the fetus, herein described. Maternal carbohydrate-predominant IUGR diet with maximal amounts of vitamin/mineral supplements are highly beneficial. Transamniotic isotonic D-glucose supplements via minimally invasive suprapubic extraperitonial pelvic approach and amniotomy (Sumathi Paturu's technique), with a subcutaneously implanted pregnancy port (SIPP) catheter is the additional therapy advocated.

The invention discloses a preparation method and application of a composite decellularized amniotic membrane of endometrial stem cells in the technical field related to physiological health care, including preparation of complete amniotic membrane tissue, preparation of a translucent amniotic membrane, immersion disinfection, decellularization treatment, preparation of a stem cell amniotic membrane culture system, preparation and cultivation of endometrial stem cell composite decellularized amniotic membrane and other processes as well as cryopreservation, thawing and application. The endometrial stem cell composite decellularized amniotic membrane prepared by the method is applied to the preparation of endometrial repair materials, is transplanted into the endometrial injury site for repair of endometrial damage and increase the thickness of the endometrium; the decellularized amniotic membrane completely removes cells and nucleic acids, and does not produce rejection reactions in thebody; through combination of menstrual blood stem cells or endometrium stem cells with the decellularized amniotic membrane, the cells are homologous to endometrial cells, and the repair effect is good; the use of hormones in repair is completely excluded to avoid interference with the internal secretion of a human body.

A medical cornea patch and its preparing method are disclosed, which implants autogenous mesenchyma stem cell to amnion for being carrier to treat cornea disease. The process includes: obtaining bone marrow 10ml from healthy person in clinical practice, diluting by PBS in ratio of 1:1, adding 5ml of Ficoll, centrifuging for 20 minutes, sucking out the nebulous single nuclei cell suspension, washing three times by PBS, implanting to 10% FBS containing culture medium of a-MEM, fetching 2í‡105 cell of the fourth generation to treated amnion with size of 1.5cmí‡1.5cm after 10 to 14 days, adding to culture medium to continue culturing, till the cell grow fully of the whole amnion.

The invention provides a non-contact full-field deformation measurement method of an amniotic membrane tissue using methylene blue for speckle making, and belongs to the technical field of deformationmeasurement. The method comprises the steps of cutting an amniotic membrane sample, clamping the amniotic membrane sample on a stretcher, injecting a methylene blue solution into a fine particle sprayer, releasing the methylene blue solution in a space above the amniotic membrane by using the sprayer above the amniotic membrane sample, and enabling the methylene blue solution to freely fall ontothe surface of the amniotic membrane under the action of gravity; then checking speckle morphology, ensuring that speckles completely cover the surface to be measured, collecting deformation images byusing a high-resolution camera, and optimizing DIC calculation parameters by using a morphological method; and finally, conducting DIC calculation to obtain a full-field deformation result of the biological membrane tissue. The method is suitable for manufacturing speckle patterns of biological film tissues such as amniotic membrane biological tissues, has the characteristics of good speckle adhesiveness, no toxicity or harm, rapidness and simplicity in implementation and easiness in operation, and is low in cost and convenient for large-scale popularization and use.

The invention discloses a breathable amnioscope, and relates to medical instruments. The breathable amnioscope comprises a conjunctival sac supporting device. The conjunctival sac supporting device isannular and attached to the radian of the ocular surface. A plurality of through holes are formed in the conjunctival sac supporting device. Compared with the prior art, the breathable amnioscope ofthe present invention can drain effusion generated by the ocular surface below the conjunctival sac supporting device, and can conduct ventilation and air exchange on the lower part of the conjunctival sac supporting device, thereby inhibiting breeding of anaerobic bacteria. The breathable amnioscope solves the problem that apocenosis and ventilation cannot be achieved in the prior art.

The invention relates to a drug-containing tissue graft as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) longitudinally cutting an umbilical cord, removing veins and arteries, and preparing a blank tissue graft containing amnion and Wharton jelly; (2) introducing a drug solution into the blank tissue graft prepared in the step (1) to obtain a drug-containing tissue graft; the introducing method comprises injection or soaking. The method disclosed by the invention is simple to operate, and the prepared drug-containing tissue graft has a very good drug slow-release function.

The present invention relates to a contact lens-type dressing manufactured by using a partially cured amniotic membrane dressing and a method of manufacturing same. The method of manufacturing a partially cured contact lens-type amniotic membrane dressing, and the partially cured contact lens-type amniotic membrane dressing of the present invention have a simple manufacturing method, can produce a contact lens-type amniotic membrane without foreign matter, have excellent biocompatibility, have excellent lens compatibility such as transparency and tensile strength compared to a fully cured contact lens-type amniotic membrane dressing, and also have excellent wound healing effects, and therefore, can be effectively used for the treatment of eye diseases such as corneal damage.

The invention relates to a method for preserving umbilical cord membrane and preparing stem cells. The umbilical cord membrane does not need to be attached to the wall during separation and culture, and the isolated mesenchymal stem cells have higher purity than that by an ordinary wartongel jelly tissue block adherence method. The warton jelly contains certain fibroblasts, which are very similarin characteristics to the mesenchymal stem cells and difficult to purify. The human amniotic membrane contains only two types of human amniotic epithelial cells and human amniotic mesenchymal stem cells. The epithelial cells have strong adherence ability and are easily removed during subculture, so that the obtained mesenchymal stem cells have higher purity. The method extracts the mesenchymal stem stem cells from the amniotic membrane layer covered by the outermost surface of the umbilical cord, and can effectively freeze and preserve the umbilical cord tissue for a long time, a frozen storage solution fully contacts the umbilical cord membrane, so that the activity of the cells on both sides of the umbilical cord membrane can be maximally maintained, resuscitation is convenient, especially separation of mesenchymal stem cells after resuscitation, and adherence treatment of umbilical cord tissue blocks cannot be required.

The invention belongs to the technical field of stem cells, and particularly relates to a universal preserving fluid for human umbilical cord, amniotic membrane and placenta samples and a preparationmethod thereof. In the universal preservation solution, the DMEM basal culture medium provides the most basic nutrition for the mesenchymal stem cells of the sample; insulin can promote the sample mesenchymal stem cells to absorb and utilize sugar in the universal preservation solution, and the cell activity is maintained; the human serum albumin provides dynamic balance for the mesenchymal stem cells and maintains cell osmotic pressure; vitamin C can prevent free radicals generated by long-time oxidation from damaging the mesenchymal stem cells; the EGF can promote the proliferation of the mesenchymal stem cells and maintain the original form of the cells. Experimental results show that the preserving fluid can be used for preserving umbilical cords, amnions and placentas for a long time,the number of obtained mesenchymal stem cells is large, the survival rate is high, and human albumin, insulin, vitamin C and EGF have a synergistic effect on increasing the number of preserved umbilical cord mesenchymal stem cells and increasing the survival rate of the mesenchymal stem cells.